AT501174T - Antibodies to MAdCAM - Google Patents

Antibodies to MAdCAM

Info

Publication number
AT501174T
AT501174T AT05711290T AT05711290T AT501174T AT 501174 T AT501174 T AT 501174T AT 05711290 T AT05711290 T AT 05711290T AT 05711290 T AT05711290 T AT 05711290T AT 501174 T AT501174 T AT 501174T
Authority
AT
Austria
Prior art keywords
madcam
antibodies
Prior art date
Application number
AT05711290T
Other languages
German (de)
Inventor
Nicholas Pullen
Elizabeth Molloy
Sirid-Aimee Kellermann
Larry L Green
Mary Haak-Frendscho
Original Assignee
Pfizer
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US53549004P priority Critical
Application filed by Pfizer, Amgen Fremont Inc filed Critical Pfizer
Priority to PCT/US2005/000370 priority patent/WO2005067620A2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34794356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT501174(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of AT501174T publication Critical patent/AT501174T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
AT05711290T 2004-01-09 2005-01-07 Antibodies to MAdCAM AT501174T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US53549004P true 2004-01-09 2004-01-09
PCT/US2005/000370 WO2005067620A2 (en) 2004-01-09 2005-01-07 ANTIBODIES TO MAdCAM

Publications (1)

Publication Number Publication Date
AT501174T true AT501174T (en) 2011-03-15

Family

ID=34794356

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05711290T AT501174T (en) 2004-01-09 2005-01-07 Antibodies to MAdCAM
AT10150359T AT522547T (en) 2004-01-09 2005-01-07 Antibodies to MAdCAM

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT10150359T AT522547T (en) 2004-01-09 2005-01-07 Antibodies to MAdCAM

Country Status (37)

Country Link
US (5) US9328169B2 (en)
EP (2) EP2177537B1 (en)
JP (7) JP4315982B2 (en)
KR (2) KR20120048644A (en)
CN (1) CN1956738B (en)
AP (1) AP200603689A0 (en)
AR (1) AR047372A1 (en)
AT (2) AT501174T (en)
AU (1) AU2005204678B2 (en)
BR (1) BRPI0506768A (en)
CA (1) CA2552523A1 (en)
CR (1) CR8485A (en)
DE (1) DE602005026779D1 (en)
DK (1) DK2177537T3 (en)
DO (1) DOP2005000002A (en)
EA (1) EA012872B1 (en)
EC (1) ECSP066741A (en)
ES (2) ES2372733T3 (en)
HK (1) HK1099695A1 (en)
IL (1) IL176749D0 (en)
MA (1) MA28430B1 (en)
MX (2) MX350383B (en)
MY (1) MY140862A (en)
NL (1) NL1027975C2 (en)
NO (1) NO342054B1 (en)
NZ (1) NZ548702A (en)
OA (1) OA13358A (en)
PA (1) PA8621301A1 (en)
PE (1) PE10532005A1 (en)
PT (1) PT2177537E (en)
SI (1) SI2177537T1 (en)
SV (1) SV2006001990A (en)
TN (1) TNSN06216A1 (en)
TW (2) TWI363762B (en)
UY (1) UY28716A1 (en)
WO (1) WO2005067620A2 (en)
ZA (1) ZA200605825B (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1399483E (en) 2001-01-05 2010-07-20 Pfizer Antibodies to insulin-like growth factor i receptor
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc CD40 antibodies
MXPA05008617A (en) * 2003-02-13 2005-11-04 Pfizer Prod Inc Uses of anti-insulin-like growth factor i receptor antibodies.
CN1833030B (en) 2003-05-22 2014-07-23 美国弗劳恩霍夫股份有限公司 Recombinant carrier molecule for expression, delivery and purification of target polypeptides
AT501174T (en) 2004-01-09 2011-03-15 Pfizer Antibodies to MAdCAM
RS57636B1 (en) 2004-09-03 2018-11-30 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
NZ561137A (en) * 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
TWI544076B (en) 2005-03-31 2016-08-01 Chugai Pharmaceutical Co Ltd
ES2351057T3 (en) 2005-07-08 2011-01-31 Pfizer Limited MAdCAM antibodies.
WO2007007160A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
MX2008000659A (en) * 2005-07-11 2008-03-13 Pfizer Ltd New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis.
WO2007007151A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
KR101446025B1 (en) 2005-08-03 2014-10-01 아이바이오, 인크. Compositions and methods for production of immunoglobulins
JP5144499B2 (en) 2006-03-31 2013-02-13 中外製薬株式会社 Antibodies modified method for the purification of bispecific antibody
EP2006381B1 (en) * 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
US7745584B2 (en) * 2006-05-22 2010-06-29 California Institute Of Technology Antibodies to sulfated carbohydrates
EP1878747A1 (en) * 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US20080124272A1 (en) * 2006-09-15 2008-05-29 Vidadi Yusibov Influenza antibodies, compositions, and related methods
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2178558B1 (en) 2007-07-11 2014-04-30 iBio, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
ES2566957T3 (en) 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha modified antibody constant region
JP5334319B2 (en) 2007-09-26 2013-11-06 中外製薬株式会社 Methods for modifying the isoelectric point of the antibody by amino acid substitutions Cdr
US8912149B1 (en) 2007-11-28 2014-12-16 California Institute Of Technology Glycosaminoglycan mimetics
KR101643005B1 (en) 2007-12-05 2016-07-28 추가이 세이야쿠 가부시키가이샤 Anti-NR10 antibody and use thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
CN102124344B (en) * 2008-05-16 2015-04-01 霍夫曼-拉罗奇有限公司 Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
EP2409990A4 (en) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd Antibody constant region variant
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
AU2010226391C1 (en) 2009-03-20 2016-11-24 Amgen Inc. Carrier immunoglobulins and uses thereof
EA201171148A1 (en) * 2009-03-20 2012-04-30 Эмджен Инк. Antagonist antibody specific to a heterodimer of the alpha-4-beta-7
RU2011151069A (en) 2009-05-15 2013-06-20 Чугаи Сейяку Кабусики Кайся Anti-axl antibody
JP5837821B2 (en) 2009-09-24 2015-12-24 中外製薬株式会社 Antibody constant region variants
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US20110158982A1 (en) * 2009-10-05 2011-06-30 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM
EP2552956A1 (en) * 2010-03-26 2013-02-06 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
BR112013006679A2 (en) 2010-09-22 2016-06-07 Amgen Inc immunoglobulins and their carriers in the use
WO2012067176A1 (en) 2010-11-17 2012-05-24 中外製薬株式会社 Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN102603649B (en) * 2011-01-20 2016-05-25 赣南师范学院 Dibazol kind of fluorescent probe compounds and methods of lead molecules
AR085091A1 (en) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc anti-kit antibodies and their uses
TW201817745A (en) 2011-09-30 2018-05-16 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
EP3070104B1 (en) 2011-04-19 2017-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
MX2013013096A (en) 2011-05-10 2014-07-14 Nestec Sa Methods of disease activity profiling for personalized therapy management.
TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd
TWI596113B (en) 2012-07-25 2017-08-21 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
SG11201507226YA (en) 2013-03-15 2015-10-29 Protagonist Therapeutics Inc Hepcidin analogues and uses therof
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CN105517571A (en) 2013-06-24 2016-04-20 中外制药株式会社 Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
MX2016003103A (en) 2013-09-20 2016-05-26 Squibb Bristol Myers Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors.
JP2017518494A (en) 2014-05-16 2017-07-06 アムジェン インコーポレイテッド Assays to detect Th1 and th2 cell populations
JP2017522362A (en) 2014-05-16 2017-08-10 プロタゴニスト セラピューティクス, インコーポレイテッド α4β7 integrin thioether peptide antagonist
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
KR20170033372A (en) 2014-07-17 2017-03-24 프로타고니스트 테라퓨틱스, 인코포레이티드 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EA201790674A1 (en) 2014-09-26 2017-08-31 Чугаи Сейяку Кабусики Кайся Inducing cytotoxicity therapeutic agent
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US9809623B2 (en) 2014-10-01 2017-11-07 Protagonist Therapeutics, Inc. α4β7 peptide monomer and dimer antagonists
JP2017537105A (en) 2014-11-26 2017-12-14 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Vedolizumab for the treatment of Crohn's disease with fistula
KR20180054923A (en) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP6174782B2 (en) 2014-12-19 2017-08-02 中外製薬株式会社 Anti-c5 antibodies and methods of use
CA2916283A1 (en) 2015-01-09 2016-07-09 Pfizer Inc. Dosage regimen for madcam antagonists
AU2016216079A1 (en) 2015-02-05 2017-07-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, Fc region variants, IL-8-binding antibodies, and uses therof
KR20180120706A (en) 2016-03-14 2018-11-06 밀레니엄 파머슈티컬스 인코퍼레이티드 How to prevent graft-versus-host disease
WO2017160700A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
KR101877349B1 (en) 2016-08-05 2018-07-17 농업회사법인 주식회사 한라종합식품 Preparation method of burned Dendropanax morbifera salt
WO2018170099A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
WO2018217989A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2019014572A1 (en) * 2017-07-14 2019-01-17 Pfizer, Inc. Antibodies to madcam
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (en) 1985-04-01 1990-02-15 Celltech Ltd A transformed myeloma cell line and the same method using the expression of a gene encoding a eukaryotic polypeptide.
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) * 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5151540A (en) * 1986-11-26 1992-09-29 Hoechst Celanese Corporation Thio carbamates and their derivatives
US5750172A (en) * 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AT439435T (en) 1991-03-01 2009-08-15 Dyax Corp Chimeric protein with micro-protein disulfide bonds with two or more and embodiments thereof
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) * 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US20040010810A1 (en) * 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566D1 (en) * 1990-01-12 2007-04-26 Amgen Fremont Inc Formation of xenogenic antibodies
US5151510A (en) * 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3540315B2 (en) 1991-09-23 2004-07-07 ケンブリッジ アンティボディー テクノロジー リミティド Production of chimeric antibodies - a combination approach
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council Procedures for producing members of specific binding partners.
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2090473A1 (en) * 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
PT100379B (en) 1991-04-10 1999-01-29 Scripps Research Inst heterodimeric receptors using phagemid libraries
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for antibody screening
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH05244982A (en) * 1991-12-06 1993-09-24 Biotest Ag Humanized b-b10
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
AT208374T (en) * 1992-02-18 2001-11-15 Otsuka Kagaku Kk Beta-lactam and cepham compounds and their production
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5643763A (en) * 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
MX9706049A (en) 1995-02-10 1998-02-28 Leukosite Inc Mucosal vascular addressins and uses thereof.
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2218489A1 (en) * 1995-04-21 1996-10-24 Aya Jakobovits Generation of large genomic dna deletions
DE69637481D1 (en) 1995-04-27 2008-05-15 Amgen Fremont Inc Dating from immunized Xenomäusen human antibodies to IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997007671A1 (en) 1995-08-29 1997-03-06 Kirin Beer Kabushiki Kaisha Chimeric animal and method for constructing the same
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) * 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1060193A2 (en) 1998-03-03 2000-12-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
IL139129D0 (en) * 1998-05-13 2001-11-25 Genentech Inc Diagnosis and treatment of hepatic disorders
US7090845B2 (en) * 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
BR9916853A (en) 1998-12-23 2001-11-20 Pfizer Monoclonal antibodies to human CTLA-4
CA2382161A1 (en) * 1999-09-03 2001-03-15 Human Genome Sciences, Inc. Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies
US6517529B1 (en) * 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
JP2003089656A (en) * 2001-09-19 2003-03-28 Nippon Kayaku Co Ltd Inhibitory agent against immune response caused by transplantation
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc CD40 antibodies
PT1485127E (en) 2002-02-25 2011-09-07 Elan Pharm Inc Administration of agents for the treatment of inflammation
US20070202097A1 (en) 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
DK1610820T4 (en) 2003-04-04 2013-11-04 Genentech Inc High concentration antibody and protein formulations
AT501174T (en) * 2004-01-09 2011-03-15 Pfizer Antibodies to MAdCAM
ZA200606557B (en) 2004-02-06 2008-02-27 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
NZ561137A (en) * 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
EP1904103A2 (en) 2005-07-08 2008-04-02 Pfizer Limited Use of anti-madcam antibodies for the treatment of coeliac disease and tropical sprue
ES2351057T3 (en) * 2005-07-08 2011-01-31 Pfizer Limited MAdCAM antibodies.
MX2008000659A (en) 2005-07-11 2008-03-13 Pfizer Ltd New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis.
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
WO2007007160A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
WO2007007151A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders

Also Published As

Publication number Publication date
AR047372A1 (en) 2006-01-18
AU2005204678A1 (en) 2005-07-28
JP2015226539A (en) 2015-12-17
UY28716A1 (en) 2005-08-31
NO20063601L (en) 2006-08-08
IL176749D0 (en) 2006-10-31
US20080124339A1 (en) 2008-05-29
TWI366570B (en) 2012-06-21
ES2362667T3 (en) 2011-07-11
TW200535144A (en) 2005-11-01
MY140862A (en) 2010-01-29
CA2552523A1 (en) 2005-07-28
ECSP066741A (en) 2006-10-31
EA012872B1 (en) 2009-12-30
USRE45847E1 (en) 2016-01-19
NZ548702A (en) 2009-06-26
BRPI0506768A (en) 2007-05-22
AU2005204678B2 (en) 2008-09-25
ES2372733T3 (en) 2012-01-25
JP5836896B2 (en) 2015-12-24
NL1027975C2 (en) 2005-12-23
PT2177537E (en) 2011-12-13
DOP2005000002A (en) 2005-08-15
US9328169B2 (en) 2016-05-03
CN1956738A (en) 2007-05-02
JP2009005695A (en) 2009-01-15
NL1027975A1 (en) 2005-07-12
JP4315982B2 (en) 2009-08-19
DK2177537T3 (en) 2011-12-12
KR20120048644A (en) 2012-05-15
US10259872B2 (en) 2019-04-16
US20050232917A1 (en) 2005-10-20
JP2018148901A (en) 2018-09-27
EP2177537B1 (en) 2011-08-31
JP5094818B2 (en) 2012-12-12
MX350383B (en) 2017-09-04
JP2008505606A (en) 2008-02-28
SV2006001990A (en) 2006-01-30
AT522547T (en) 2011-09-15
WO2005067620A8 (en) 2006-09-21
EP1709080A2 (en) 2006-10-11
US20170051057A1 (en) 2017-02-23
HK1099695A1 (en) 2014-03-07
ZA200605825B (en) 2007-11-28
PE10532005A1 (en) 2005-12-12
US20070166308A1 (en) 2007-07-19
JP4729076B2 (en) 2011-07-20
PA8621301A1 (en) 2006-09-22
JP6215875B2 (en) 2017-10-18
OA13358A (en) 2007-04-13
JP2010042025A (en) 2010-02-25
US7932372B2 (en) 2011-04-26
JP2012250982A (en) 2012-12-20
CN1956738B (en) 2013-05-29
EA200601297A1 (en) 2007-02-27
TWI363762B (en) 2012-05-11
EP2177537A3 (en) 2010-05-05
MA28430B1 (en) 2007-02-01
WO2005067620A2 (en) 2005-07-28
SI2177537T1 (en) 2012-01-31
DE602005026779D1 (en) 2011-04-21
EP1709080A4 (en) 2008-03-19
AP200603689A0 (en) 2006-08-31
MXPA06007843A (en) 2007-01-26
JP2017079789A (en) 2017-05-18
CR8485A (en) 2007-02-22
KR20060129006A (en) 2006-12-14
WO2005067620A3 (en) 2005-09-29
TNSN06216A1 (en) 2007-12-03
NO342054B1 (en) 2018-03-19
WO2005067620A9 (en) 2009-10-01
EP1709080B1 (en) 2011-03-09
AU2005204678A2 (en) 2005-07-28
JP6423024B2 (en) 2018-11-14
EP2177537A2 (en) 2010-04-21
TW201217397A (en) 2012-05-01

Similar Documents

Publication Publication Date Title
AT539708T (en) Wirbelfazettengelenkprothese
AT536418T (en) Lipidverkapselte interference-rna
AT543462T (en) Allo-implant
AT462363T (en) Polyaxialpedikelschraubenanordung
AT415976T (en) Brombeerextrakt
AT381540T (en) Oximesther-photoinitiators
DE602004014644D1 (en) Teantrieb
DE602004011270D1 (en) Auslasszusatzmodul
AT360450T (en) Sicherheitsdauerverweilnadel
AT415112T (en) Abschminkapplikator
AT473021T (en) Nichtkräuselnde polyhydroxyalkanoatnähte
DE602004025621D1 (en) Stentreduziersystem
AT455498T (en) Zenteseinstrument
AT447853T (en) Enyzmgranulat
NO340827B1 (en) Anti-IL-17 antibodies
AT421266T (en) umbrella
AT371694T (en) Mq-t propylsiloxanharze
DE602005026015D1 (en) Antiadhäsionssperrschicht
AT526869T (en) Hydratationsmonitor
AT535227T (en) Selbsterwärmendes rasierschaumprodukt
DK1737891T3 (en) Anti-P-selectin antibodies
LTC1776142I2 (en) IL-17 antagonist antibodies
DE602005016654D1 (en) Ltungssystem
DE602005011456D1 (en) propylencopolymerzusammensetzungen Highly transparent
AT442115T (en) Unterkiefervorschiebeorthese

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties